ReviewPathologica2021
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives.
Review in Pathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 709 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
709 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Clinical efficacy and safety outcomes of anlotinib therapy in sarcoma: a systematic review and meta-analysis.Journal of the Egyptian National Cancer Institute · 2026Pooled it
- Assessing Treatment Response in Soft Tissue Sarcoma Using Dynamic Contrast-Enhanced MRI: A Systematic Review.Korean journal of radiology · 2026Pooled it
- MRI findings for differentiating benign and malignant soft tissue tumors: a systematic review-part 2: key imaging findings.Skeletal radiology · 2026Pooled it
- Management of intracranial undifferentiated pleomorphic sarcoma: a systematic review.Neurosurgical review · 2026Pooled it
- Synovial chondromatosis of the temporomandibular joint: a case report with an associated systematic review update of the literature.Journal of oral & facial pain and headache · 2025Pooled it
- Camrelizumab Plus Apatinib in Advanced Unresectable Alveolar Soft Part Sarcoma and Undifferentiated Pleomorphic Sarcoma Patients: A Single-Center, Exploratory Case Series.Therapeutics and clinical risk management · 2026Trial
- Uterine angiomatosis as an unexpected cause of refractory pelvic pain and heavy menstrual bleeding: a case report and literature review.Case reports in women's health · 2026Article
- Pleural desmoid tumor mimicking a myofibroblastic neoplasm: Imaging-pathologic correlation.Radiology case reports · 2026Article
- Anthropometric factors, physical activity, and the risk of soft tissue sarcoma: a case-control study.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- Apparent diffusion coefficient metrics for treatment response assessment in soft tissue sarcoma: Reproducibility and prognostic value of whole-tumor and sub-regional analysis.Skeletal radiology · 2026Article
- Atypical spindle cell/pleomorphic lipomatous tumor with sarcomatous transformation during recurrence.Skeletal radiology · 2026Article
- Soft Tissue Reporting and Data System (Soft Tissue-RADS): preliminary validation among fellowship-trained musculoskeletal radiologists.European radiology · 2026Article
- MRI-Based radiomic signature for predicting pathologic treatment response to neoadjuvant chemoradiotherapy and radioimmunotherapy in soft tissue sarcoma.Skeletal radiology · 2026Article
- Rare case of dedifferentiated liposarcoma of the pectoralis major muscle found on screening mammography.Radiology case reports · 2026Article
- Fat-Containing Soft Tissue Lesions of the Limbs and Body Wall-A Pictorial Essay.Journal of medical imaging and radiation oncology · 2026Review
- Multi-b-value diffusion-weighted imaging-based habitat imaging for preoperative prediction of histological grade and prognosis in soft tissue sarcoma: focusing on intratumoral heterogeneity.Quantitative imaging in medicine and surgery · 2026Article
- Multifocal primary hepatic epithelioid hemangioendothelioma: a case in which tumor biopsy was critical to prevent misdiagnosis.Clinical journal of gastroenterology · 2026Article
- A case of retroperitoneal dedifferentiated liposarcoma.Radiology case reports · 2026Article
- Inflammatory myofibroblastic tumor of the psoas muscle presenting as a retroperitoneal mass: a case report.International journal of surgery case reports · 2026Article
- Dural CIC::DUX4 sarcoma presenting with intracranial hemorrhage at both initial diagnosis and recurrence: a case report and literature review.Brain tumor pathology · 2026Article
649 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal tumours represent one of the most challenging field of diagnostic pathology and refinement of classification schemes plays a key role in improving the quality of pathologic diagnosis and, as a consequence, of therapeutic options. The recent publication of the new WHO classification of Soft Tissue Tumours and Bone represents a major step toward improved standardization of diagnosis. Importantly, the 2020 WHO classification has been opened to expert clinicians that have further contributed to underline the key value of pathologic diagnosis as a rationale for proper treatment. Several relevant advances have been introduced. In the attempt to improve the prediction of clinical behaviour of solitary fibrous tumour, a risk assessment scheme has been implemented. NTRK-rearranged soft tissue tumours are now listed as an "emerging entity" also in consideration of the recent therapeutic developments in terms of NTRK inhibition. This decision has been source of a passionate debate regarding the definition of "tumour entity" as well as the consequences of a "pathology agnostic" approach to precision oncology. In consideration of their distinct clinicopathologic features, undifferentiated round cell sarcomas are now kept separate from Ewing sarcoma and subclassified, according to the underlying gene rearrangements, into three main subgroups (CIC, BCLR and not ETS fused sarcomas) Importantly, In order to avoid potential confusion, tumour entities such as gastrointestinal stroma tumours are addressed homogenously across the different WHO fascicles. Pathologic diagnosis represents the integration of morphologic, immunohistochemical and molecular characteristics and is a key element of clinical decision making. The WHO classification is as a key instrument to promote multidisciplinarity, stimulating pathologists, geneticists and clinicians to join efforts aimed to translate novel pathologic findings into more effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.